Posts Tagged 'actos study'

Hissey Kientz publishes frequently asked questions for Actos bladder cancer

Hissey Kientz law firm has published a frequently asked questions section to provide more information about the diabetes medication Actos and bladder cancer to readers. The FAQs include information concerning who should not take Actos and certain risks associated with the drug.

Read more about the connection between Actos and bladder cancer…

Judge allows company to sell generic Actos

A U.S. District Judge has allowed a company to begin immediately selling generic Actos, despite resistance from the Food and Drug Administration (FDA). Watson Pharmaceuticals will begin marketing the generic version of the top-selling type II diabetes drug Actos, which has come under fire for health concerns.

Read more about the generic version of Actos…

 

Actos doubles bladder cancer risk, British study finds

A new study has confirmed that the diabetes medication Actos doubles the risk of developing bladder cancer among people who use the drug for at least two years. The Canadian study was published in the British Medical Journal (BMJ) and included more than 115,000 diabetes patients that were treated between 1988 and 2009.

Read more about Actos and bladder cancer…

Experts weigh Actos alternatives after cancer warning

Two new reports filed by the American College of Physicians and Consumer Reports have found that taking an alternative to the diabetes drug Actos has significant advantages for type II diabetes patients. The physicians found that diabetes medication metformin—which has existed for nearly two decades—is both cheaper and safer than Actos.

Read more about alternatives to Actos…

FDA Mulling End to Avandia-Actos Trial on Safety Worries

The FDA is considering cutting short a trial comparing the safety of two diabetes drugs — GlaxoSmithKline’s Avandia and Takeda’s Actos, the WSJ reports. Given that Avandia has been linked since 2007 to an increased risk of heart attacks, some scientists have said it’s not ethical to put study participants at risk. If the trial is stopped, the FDA will also consider asking Glaxo to stop selling the drug.

Click here to read more…


Enter your email address to subscribe to this blog and receive notifications of new posts by email.

Join 437 other followers

Contact Us:

Hissey Kientz, LLP

9442 Capital of Texas Hwy N.

Arboretum Plaza One, Suite 400

Austin, Texas 78759

Toll-free: (866) 275-4454

Facsimile: (512) 320-9101

Email: info@hkllp.com

Sponsored By:

Hissey Kientz, LLP (Austin, TX)

Attorney Michael Hissey is responsible for the content of this website.